Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart |
| |
Authors: | Jeffry D Shearer Lisa Henning Daniel C Sanford Na Li Mario H Skiadopoulos Joshua J Reece Boris Ionin Vladimir Savransky |
| |
Institution: | 1. Emergent BioSolutions Inc., 300 Professional Drive, Gaithersburg, MD 20879, USA;2. Battelle Biomedical Research Center, Columbus, OH 43201, USA |
| |
Abstract: | The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for post-exposure prophylaxis (PEP) against inhalational anthrax. In clinical studies, two vaccinations with AV7909 administered either two or four weeks apart induced an enhanced immune response compared to BioThrax® (Anthrax Vaccine Adsorbed) (AVA). Anthrax toxin-neutralizing antibody (TNA) levels on Day 70 following initial vaccination that were associated with protection of animals exposed to inhalational anthrax were previously reported for the 0, 4-week AV7909 vaccination regimen. The current study shows that a 0, 2-week AV7909 vaccination regimen protected guinea pigs (GPs) and nonhuman primates (NHPs) against a lethal inhalational anthrax challenge on Days 28 and 70 after the first immunization. An earlier induction of protective TNA levels using a 0, 2-week AV7909 vaccination regimen may provide benefit over the currently approved AVA PEP 0, 2, and 4-week vaccination regimen. |
| |
Keywords: | Animal rule Correlates of protection TNA threshold Anthrax vaccine CPG 7909 adjuvant Guinea pig Cynomolgus macaque |
本文献已被 ScienceDirect 等数据库收录! |
|